戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ndiceal mucocele 2 years after risk-reducing salpingo-oophorectomy.
2 eillance for ovarian cancer or risk-reducing salpingo-oophorectomy.
3 c total abdominal hysterectomy and bilateral salpingo-oophorectomy.
4 ration with total hysterectomy and bilateral salpingo-oophorectomy.
5 ty-sparing surgery in the form of unilateral salpingo-oophorectomy.
6 men who had undergone prophylactic bilateral salpingo-oophorectomy (47 women) were matched with mutat
7  approximately 4 years with hysterectomy and salpingo-oophorectomy and adherence to colorectal cancer
8 in 3 of the 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cancer was diagnose
9                                              Salpingo-oophorectomy and/or mastectomy are currently th
10 g total abdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles
11   Total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy reveal
12 oreduction including hysterectomy, bilateral salpingo-oophorectomy, appendectomy, resection of pelvic
13                               Mastectomy and salpingo-oophorectomy are widely used by carriers of BRC
14                                Risk-reducing salpingo-oophorectomy at currently recommended age or RR
15                       Bilateral prophylactic salpingo-oophorectomy (BPSO) is used widely used to redu
16   To mitigate ovarian cancer risk, bilateral salpingo-oophorectomy (BSO) is commonly recommended for
17 fer between women with and without bilateral salpingo-oophorectomy (BSO) is unknown.
18 associations between hysterectomy, bilateral salpingo-oophorectomy (BSO), and incidence of diabetes i
19 ed with women without surgery; risk-reducing salpingo-oophorectomy decreased breast cancer incidence
20 related gynecologic cancer was longer in the salpingo-oophorectomy group, with a hazard ratio for sub
21 g salpingo-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer
22                                 Prophylactic salpingo-oophorectomy has been demonstrated to decrease
23                                Risk-reducing salpingo-oophorectomy has been shown to reduce ovarian c
24 Age was varied at hysterectomy and bilateral salpingo-oophorectomy (hyst-BSO) and at surveillance ini
25                                              Salpingo-oophorectomy in carriers of BRCA mutations can
26  of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations.
27 with prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome.
28 hat prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy for preve
29                                   Preventive salpingo-oophorectomy is currently the only method known
30 n cancer mortality, but preventive bilateral salpingo-oophorectomy is highly effective at preventing
31 ncer in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the appendix.
32                         Preventive bilateral salpingo-oophorectomy is offered to women at high risk o
33                                Risk-reducing salpingo-oophorectomy is often considered by carriers of
34                         Preventive bilateral salpingo-oophorectomy is recommended to women with a BRC
35    Tamoxifen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or su
36 dbearing age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that ca
37 tan areas were higher for minimally invasive salpingo-oophorectomy (odds ratio [OR], 1.62; 95% CI, 1.
38 nsists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive ap
39 age II), is surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy)
40 g 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm
41 udies have investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously
42 nsus division for all 10 operations (eg, MIS salpingo-oophorectomy range, 29.6%-58.8%; P < .001).
43 f total abdominal hysterectomy and bilateral salpingo-oophorectomy revealed similar estimates (HR, 0.
44                      Risk-reducing bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastecto
45 ated the cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) and, where relevant, risk-r
46                                Risk-reducing salpingo-oophorectomy (RRSO) has been widely adopted as
47                                Risk-reducing salpingo-oophorectomy (RRSO) is effective in decreasing
48            Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among
49                                Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovari
50 rnative prevention strategy to risk-reducing salpingo-oophorectomy (RRSO) that avoids detrimental con
51                                Risk-reducing salpingo-oophorectomy (RRSO) was encouraged throughout t
52                          After risk-reducing salpingo-oophorectomy (RRSO), BRCA1/2 pathogenic variant
53 as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified
54 l risk reduction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become an important co
55 k-reducing mastectomy (RRM) or risk-reducing salpingo-oophorectomy (RRSO), or both procedures, with s
56  increasingly choose bilateral risk-reducing salpingo-oophorectomy (RRSO).
57  ovarian carcinoma prevention: risk-reducing salpingo-oophorectomy (RRSO).
58 as risk-reducing mastectomy or risk-reducing salpingo-oophorectomy (RRSO).
59 r carriers of these mutations, risk-reducing salpingo-oophorectomy significantly reduces morbidity an
60 sk of ovarian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidenc
61      BRCA carriers are offered risk-reducing salpingo-oophorectomy to reduce their ovarian cancer ris
62 oprevention, or risk-reducing mastectomy and salpingo-oophorectomy, to reduce cancer risk.
63 with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy
64 a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk o
65                                Risk-reducing salpingo-oophorectomy was associated with a reduced risk
66 k-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-caus
67                                 Prophylactic salpingo-oophorectomy was not associated with risk of co
68  relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes.
69 ctively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovar
70 with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-ooph